TARGETING METTL3 TO OVERCOME DRUG RESISTANCE IN METASTATIC CLEAR CELL RENAL CELL CARCINOMA

$323,000FY2025Defense Health AgencyDOD

The Methodist Hospital Research Institute, Houston TX

Investigators